Skip to main content
Erschienen in:

01.08.2011 | Leitthema

Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms

verfasst von: Dr. W.E.E. Eberhardt, T.C. Gauler, S. Welter, T. Krbek, M. Stuschke, C. Pöttgen

Erschienen in: Die Onkologie | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Stadium III des nichtkleinzelligen Lungenkarzinoms (NSCLC) ist durch eine außerordentliche Heterogenität der Krankheitssituationen gekennzeichnet. Neben der überarbeiteten Stadieneinteilung nach IASLC/UICC kommt einer Vielzahl von prognostischen Faktoren und modalitätsbezogenen Einflussfaktoren entscheidende Bedeutung zu. Da es in diesen Stadien um eine realistische Chance auf Kuration für 20–35% der Patienten geht – je nach Risikokonstellation –, sollten diese Patienten grundsätzlich von Behandlungsgruppen mit hoher interdisziplinärer Kommunikation und Kompetenz betreut werden. Leider laufen aktuell in diesen so wichtigen Behandlungsstadien nur wenige prospektive randomisierte klinische Studien. Zur flächendeckenden Qualitätssicherung für diese Patientengruppen kommt deshalb in Zukunft in besonderem Maße den interdisziplinären Lungenkrebszentren eine federführende Rolle zu. Eine Kombination aus Systemtherapie sowie lokalen Maßnahmen wie Radiatio und bei ausgewählten Fällen Operation bedarf einer engen gegenseitigen Abstimmung in möglichst klar definierten multimodalen Behandlungsprotokollen. Eine Verbesserung der Therapieergebnisse wird aktuell besonders durch eine individualisierte Therapie unter Berücksichtigung von Komorbitätsfaktoren der Patienten und ihrer bestehenden konkurrierenden Risiken sowie weiteren Innovationen der Radiotherapie erwartet. Der mögliche zukünftige Einsatz von molekular gezielten Medikamenten für definierte Patientengruppen wird aktuell für monoklonale Antikörper getestet.
Literatur
1.
Zurück zum Zitat Malvezzi M, Arfe A, Bertucci P et al (2011) European Cancer mortality prediction for the year 2011. Ann Oncol 22:947–956PubMedCrossRef Malvezzi M, Arfe A, Bertucci P et al (2011) European Cancer mortality prediction for the year 2011. Ann Oncol 22:947–956PubMedCrossRef
2.
Zurück zum Zitat Ginsberg RJ, Vokes EE, Raben A (1997) Non –small cell lung cancer. In: De Vita V Jr, Hellman S, Rosenberg SA (Hrsg) Cancer: Principles and practice of oncology, 5. Aufl. Lippincott, Philadelphia, S 858–911 Ginsberg RJ, Vokes EE, Raben A (1997) Non –small cell lung cancer. In: De Vita V Jr, Hellman S, Rosenberg SA (Hrsg) Cancer: Principles and practice of oncology, 5. Aufl. Lippincott, Philadelphia, S 858–911
3.
Zurück zum Zitat Scagliotti G, Brodowicz T, Shepherd FA et al (2011) Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6(1):64–70PubMed Scagliotti G, Brodowicz T, Shepherd FA et al (2011) Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6(1):64–70PubMed
4.
Zurück zum Zitat Goldstraw P, Crowley J, Chansky K et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2(8):706–714PubMedCrossRef Goldstraw P, Crowley J, Chansky K et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2(8):706–714PubMedCrossRef
5.
Zurück zum Zitat Vansteenkiste JF, Mortelmans LA (1999) FDG-PET in the locoregional lymph node staging of non-small cell lung cancer. A Comprehensive Review of the Leuven Lung Cancer Group Experience. Clin Positron Imaging 2(4):223–231PubMedCrossRef Vansteenkiste JF, Mortelmans LA (1999) FDG-PET in the locoregional lymph node staging of non-small cell lung cancer. A Comprehensive Review of the Leuven Lung Cancer Group Experience. Clin Positron Imaging 2(4):223–231PubMedCrossRef
6.
Zurück zum Zitat Herth FJ (2011) Nonsurgical staging of the mediastinum: EBUS and EUS. Semin Respir Crit Care Med 32(1):62–68. Epub 2011 Apr 15PubMedCrossRef Herth FJ (2011) Nonsurgical staging of the mediastinum: EBUS and EUS. Semin Respir Crit Care Med 32(1):62–68. Epub 2011 Apr 15PubMedCrossRef
7.
Zurück zum Zitat Goeckenjan G, Sitter H, Thomas M et al (2010) Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 65(1):39–59. Epub 2011 Dec 14PubMedCrossRef Goeckenjan G, Sitter H, Thomas M et al (2010) Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 65(1):39–59. Epub 2011 Dec 14PubMedCrossRef
8.
Zurück zum Zitat Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65(1):25–32PubMed Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65(1):25–32PubMed
9.
Zurück zum Zitat Eberhardt W, Wilke H, Stamatis G et al (1998) Preoperative chemotherapy followed by concurrent chemoradiotion therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16(2):622–663PubMed Eberhardt W, Wilke H, Stamatis G et al (1998) Preoperative chemotherapy followed by concurrent chemoradiotion therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16(2):622–663PubMed
10.
Zurück zum Zitat Alexander BM, Othus M, Caglar HB, Allen AM (2011) Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 79(5):1381–1387. Epub 2010 Jun 3PubMedCrossRef Alexander BM, Othus M, Caglar HB, Allen AM (2011) Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 79(5):1381–1387. Epub 2010 Jun 3PubMedCrossRef
11.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef
12.
Zurück zum Zitat Colinet B, Jacot W, Bertrand D et al (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer 93(10):1098–1105PubMedCrossRef Colinet B, Jacot W, Bertrand D et al (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer 93(10):1098–1105PubMedCrossRef
13.
Zurück zum Zitat Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991PubMedCrossRef Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991PubMedCrossRef
14.
Zurück zum Zitat Kamal NS, Soria JC, Mendiboure J et al (2010) MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 16(4):1206–1215. Epub 2010 Feb 9PubMedCrossRef Kamal NS, Soria JC, Mendiboure J et al (2010) MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 16(4):1206–1215. Epub 2010 Feb 9PubMedCrossRef
15.
Zurück zum Zitat Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. Epub 2009 Aug 19PubMedCrossRef Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. Epub 2009 Aug 19PubMedCrossRef
16.
Zurück zum Zitat Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer(FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531PubMedCrossRef Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer(FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531PubMedCrossRef
17.
Zurück zum Zitat o’Byrne K, Eberhardt W, Störkel S et al (2010) Use of a continuous EGFR IHC scoring method reveals association between tumor response and EGFR expression levels for patients receiving CT + cetuximab versus CT alone in the phase III trial FLEX in advanced NSCLC. J Thorac Oncol 5: 12 (Suppl 7):S558 o’Byrne K, Eberhardt W, Störkel S et al (2010) Use of a continuous EGFR IHC scoring method reveals association between tumor response and EGFR expression levels for patients receiving CT + cetuximab versus CT alone in the phase III trial FLEX in advanced NSCLC. J Thorac Oncol 5: 12 (Suppl 7):S558
18.
Zurück zum Zitat Rajeswaran A, Trojan A, Burnand B et al (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59(1):1–11. Epub 2007 Aug 27PubMedCrossRef Rajeswaran A, Trojan A, Burnand B et al (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59(1):1–11. Epub 2007 Aug 27PubMedCrossRef
19.
Zurück zum Zitat Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2):330–353. Epub 2003 Dec 22PubMedCrossRef Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2):330–353. Epub 2003 Dec 22PubMedCrossRef
20.
Zurück zum Zitat Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374(9687):379–386. Epub 2009 Jul 24PubMedCrossRef Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374(9687):379–386. Epub 2009 Jul 24PubMedCrossRef
21.
Zurück zum Zitat Eberhardt WE, Albain KS, Pass H et al (2003) Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 42(Suppl 1):S9–S14PubMedCrossRef Eberhardt WE, Albain KS, Pass H et al (2003) Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 42(Suppl 1):S9–S14PubMedCrossRef
22.
Zurück zum Zitat Robinson LA, Ruckdeschel J, Wagner H, Stevens C (2007) Treatment of non-small cell lung cancer stage IIIA. Chest 132:243–265CrossRef Robinson LA, Ruckdeschel J, Wagner H, Stevens C (2007) Treatment of non-small cell lung cancer stage IIIA. Chest 132:243–265CrossRef
23.
Zurück zum Zitat The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360CrossRef The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360CrossRef
24.
Zurück zum Zitat Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552–3559PubMedCrossRef Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552–3559PubMedCrossRef
25.
Zurück zum Zitat Lally BE, Zelterman D, Colasanto JM et al (2006) Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24(19):2998–3006. Epub 2006 Jun 12PubMedCrossRef Lally BE, Zelterman D, Colasanto JM et al (2006) Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24(19):2998–3006. Epub 2006 Jun 12PubMedCrossRef
26.
Zurück zum Zitat Douillard JY, Rosell R, De Lena M, Carpagnano F (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]: a randomised contolled trial. Lancet Oncol 7:719–727PubMedCrossRef Douillard JY, Rosell R, De Lena M, Carpagnano F (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]: a randomised contolled trial. Lancet Oncol 7:719–727PubMedCrossRef
27.
Zurück zum Zitat Eberhardt WE, Stamatis G, Stuschke M (2009) Surgery in stage III non-small-cell lung cancer. Lancet 374(9687):359–360. Epub 2009 Jul 24PubMedCrossRef Eberhardt WE, Stamatis G, Stuschke M (2009) Surgery in stage III non-small-cell lung cancer. Lancet 374(9687):359–360. Epub 2009 Jul 24PubMedCrossRef
28.
Zurück zum Zitat Friedel G, Budach W, Dippon J et al (2010) Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 28(6):942–948. Epub 2010 Jan 25PubMedCrossRef Friedel G, Budach W, Dippon J et al (2010) Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 28(6):942–948. Epub 2010 Jan 25PubMedCrossRef
30.
Zurück zum Zitat Meerbeeck JP van, Kramer GW, Van Schil PE et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442–450PubMedCrossRef Meerbeeck JP van, Kramer GW, Van Schil PE et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442–450PubMedCrossRef
31.
Zurück zum Zitat Betticher DC, Hsu Schmitz SF et al (2003) Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21(9):1752–1759PubMedCrossRef Betticher DC, Hsu Schmitz SF et al (2003) Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21(9):1752–1759PubMedCrossRef
32.
Zurück zum Zitat Thomas M, Rübe C, Hoffknecht P et al (2008) Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9:636–648PubMedCrossRef Thomas M, Rübe C, Hoffknecht P et al (2008) Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9:636–648PubMedCrossRef
33.
Zurück zum Zitat Nestle U, Kremp S, Grosu AL (2006) Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 81:209–225PubMedCrossRef Nestle U, Kremp S, Grosu AL (2006) Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 81:209–225PubMedCrossRef
34.
Zurück zum Zitat Eberhardt WEE, Van Schill P, Curran W Jr, Socinski MA (2010) Stage IIIB Non-Small Cell Lung Cancer. In: Pass H, Carbone DP et al (Hrsg) Principles and Practice of Lung Cancer, 4. Aufl. Chapter 56. Lippincott Williams and Wilkins, Philadelphia, S 821–836 Eberhardt WEE, Van Schill P, Curran W Jr, Socinski MA (2010) Stage IIIB Non-Small Cell Lung Cancer. In: Pass H, Carbone DP et al (Hrsg) Principles and Practice of Lung Cancer, 4. Aufl. Chapter 56. Lippincott Williams and Wilkins, Philadelphia, S 821–836
35.
Zurück zum Zitat Zatloukal P, Petruzelka L, Zemanova M et al (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46:87–98PubMedCrossRef Zatloukal P, Petruzelka L, Zemanova M et al (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46:87–98PubMedCrossRef
36.
Zurück zum Zitat Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26(35):5755–5760. Epub 2008 Nov 10PubMedCrossRef Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26(35):5755–5760. Epub 2008 Nov 10PubMedCrossRef
37.
Zurück zum Zitat Fournel P, Venengegre A, Robinet G et al (2006) Induction or consolidation chemotherapy with cisplatin and paclitaxel pluus concurrent chemoradiation with carboplatin and vinorelbin for unresectable non-small-cell lung cancer patients: randomized phase-II trial. GFPC-GLOT-IFCT 02-01. J Clin Oncol 24:7048 Fournel P, Venengegre A, Robinet G et al (2006) Induction or consolidation chemotherapy with cisplatin and paclitaxel pluus concurrent chemoradiation with carboplatin and vinorelbin for unresectable non-small-cell lung cancer patients: randomized phase-II trial. GFPC-GLOT-IFCT 02-01. J Clin Oncol 24:7048
38.
Zurück zum Zitat Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12(2):153–159. Epub 2011 Jan 11PubMedCrossRef Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12(2):153–159. Epub 2011 Jan 11PubMedCrossRef
39.
Zurück zum Zitat Eberhardt WEE, Gauler TC, Le Pechoux C et al (2011) Long-term survival (S) of induction chemotherapy (CTx) with three cycles cisplatin(cis)/paclitaxel(pac) followed by concurrent (cc) chemoradiation (CTx/RTx) cis/etoposide (eto) and 45 gy (1.5 Gy bid) plus surgery (SURG) – phase-II results (CISTAXOL). J Clin Oncol 13:29:2011 (suppl; abstr. 7042) Eberhardt WEE, Gauler TC, Le Pechoux C et al (2011) Long-term survival (S) of induction chemotherapy (CTx) with three cycles cisplatin(cis)/paclitaxel(pac) followed by concurrent (cc) chemoradiation (CTx/RTx) cis/etoposide (eto) and 45 gy (1.5 Gy bid) plus surgery (SURG) – phase-II results (CISTAXOL). J Clin Oncol 13:29:2011 (suppl; abstr. 7042)
40.
Zurück zum Zitat Pöttgen C, Eberhardt WE, Gauler T (2010) Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial. Int J Radiat Oncol Biol Phys 76(3):809–815. Epub 2009 May 7PubMedCrossRef Pöttgen C, Eberhardt WE, Gauler T (2010) Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial. Int J Radiat Oncol Biol Phys 76(3):809–815. Epub 2009 May 7PubMedCrossRef
41.
Zurück zum Zitat Kelly K, Chansky K, Gaspar LE (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26(15):2450–2456. Epub 2008 Mar 31PubMedCrossRef Kelly K, Chansky K, Gaspar LE (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26(15):2450–2456. Epub 2008 Mar 31PubMedCrossRef
42.
Zurück zum Zitat Bonner JA, Harari PM, Giralt J (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578PubMedCrossRef Bonner JA, Harari PM, Giralt J (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578PubMedCrossRef
43.
Zurück zum Zitat Stuschke M, Eberhardt W, Pöttgen C et al (1999) Prophylactic cranial irradiation in locally advanced non-small cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 17:2700–2709PubMed Stuschke M, Eberhardt W, Pöttgen C et al (1999) Prophylactic cranial irradiation in locally advanced non-small cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 17:2700–2709PubMed
44.
Zurück zum Zitat Pöttgen C, Eberhardt W, Grannass A et al (2007) Prophylactic cranial irradiation in operable stage IIIA non-small cell lung cancer treated with neoadjuvant chemo-radiotherapy – results from a German multicentre randomized trial. J Clin Oncol 25:4987–4992PubMedCrossRef Pöttgen C, Eberhardt W, Grannass A et al (2007) Prophylactic cranial irradiation in operable stage IIIA non-small cell lung cancer treated with neoadjuvant chemo-radiotherapy – results from a German multicentre randomized trial. J Clin Oncol 25:4987–4992PubMedCrossRef
45.
Zurück zum Zitat Gore EM, Bae K, Wong SJ, Sun A et al (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29(3):272–278. Epub 2010 Dec 6PubMedCrossRef Gore EM, Bae K, Wong SJ, Sun A et al (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29(3):272–278. Epub 2010 Dec 6PubMedCrossRef
46.
Zurück zum Zitat Aberle DR, Berg CD (2010) The National Lung Screening Trial (NLST) – An overview. Presentation at the Chicago Multidisciplinary Thoracic Oncology Symposium December 2010. N Engl J Med 2011;101056/N E J Med 1102:873 Aberle DR, Berg CD (2010) The National Lung Screening Trial (NLST) – An overview. Presentation at the Chicago Multidisciplinary Thoracic Oncology Symposium December 2010. N Engl J Med 2011;101056/N E J Med 1102:873
47.
Zurück zum Zitat Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703PubMedCrossRef Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703PubMedCrossRef
48.
Zurück zum Zitat Chang JY, Komaki R, Lu C et al (2011) Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. Cancer. doi: 10.1002/cncr.26080. [Epub ahead of print] Chang JY, Komaki R, Lu C et al (2011) Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. Cancer. doi: 10.1002/cncr.26080. [Epub ahead of print]
Metadaten
Titel
Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms
verfasst von
Dr. W.E.E. Eberhardt
T.C. Gauler
S. Welter
T. Krbek
M. Stuschke
C. Pöttgen
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2011
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-011-2035-7

Weitere Artikel der Ausgabe 8/2011

Die Onkologie 8/2011 Zur Ausgabe

CME Weiterbildung · Zertifizierte Fortbildung

Gutartige Weichteiltumoren in der Orthopädie

Neu im Fachgebiet Onkologie

Was das Überwachen von Risikopersonen für Pankreaskrebs bringt

12.07.2024 Pankreaskarzinom Nachrichten

Programme zur Überwachung von Hochrisikokandidaten für duktales Adenokarzinom des Pankreas führen womöglich zu früherer Diagnose. Ob sich das auch in einem Überlebensvorteil niederschlägt, hat eine Studie getestet.

Prostatakarzinome der ISUP-Gruppe 1 nicht immer harmlos

11.07.2024 Prostatakarzinom Nachrichten

Nicht bei allen Prostatakarzinomen der Gleason-Graduierungsgruppe 1 kann man davon ausgehen, dass sie benigne sind. In einer Studie aus dem UKE Hamburg hatten auch in dieser Gruppe bestimmte Patienten ein deutlich erhöhtes Risiko für einen ungünstigen Verlauf.

Taugen Risikoscores für Schlaganfall und Blutungen auch bei Krebskranken?

Britische Registerdaten sprechen dafür, dass sich die Blutungsrisikoprädiktion bei Personen mit Vorhofflimmern, die zugleich an Krebs leiden, nicht einfach aus Kohorten ohne Krebs übertragen lässt.

Weitere Studie zur adjuvanten Immuntherapie beim RCC negativ

09.07.2024 Nierenkarzinom Nachrichten

Im Vergleich mit einer alleinigen Operation konnte eine perioperative Immuntherapie das rezidivfreie Überleben bei Personen mit Hochrisiko-Nierenkarzinom in der Studie PROSPER EA8143 nicht verbessern. Ein Kommentar zur Studie ordnet die Ergebnisse ein.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.